Remove Drug Delivery Remove Filler Remove In-Vivo Remove Protein
article thumbnail

TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses

The Pharma Data

million people misused prescription opioids in 2018, and many die every day from opioid-related drug overdoses. Current intraarticular anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins. SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec.

Trials 40